Mesenchymal Stem Cell Therapy For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mesenchymal stem/stromal cells (MSCs) are multipotent cells with immunomodulatory, neurotrophic, and regenerative properties. MSC-based therapies are being investigated for Alzheimer's Disease, Parkinson's Disease, ALS, multiple sclerosis, and stroke [1]. These cells can be derived from bone marrow, adipose tissue, umbilical cord, or dental pulp [2]. [1]
MSCs secrete anti-inflammatory cytokines (IL-10, TGF-β) and inhibit pro-inflammatory immune cell activation, reducing chronic neuroinflammation characteristic of neurodegenerative diseases [3]. This immunomodulatory effect is mediated through both cell-cell contact and paracrine signaling mechanisms [4]. [2]
MSCs release neurotrophic factors including BDNF, GDNF, NGF, and VEGF, supporting neuronal survival and promoting endogenous repair mechanisms [5]. These neurotrophins can protect vulnerable neuronal populations from degeneration [6]. [3]
Most therapeutic effects are mediated through secretome (conditioned media) containing exosomes, microRNAs, and growth factors rather than direct cell replacement [7]. The MSC secretome has shown therapeutic potential in multiple neurodegeneration models [8]. [4]
MSCs can transfer healthy mitochondria to damaged neurons via tunneling nanotubes, restoring cellular energy metabolism [9]. This mitochondrial transfer has been shown to improve neuronal function in models of Parkinson's disease [10]. [5]
Phase I/II trials completed showing safety in AD patients [11]. Potential for cognitive improvement has been reported in early-stage trials [12]. Multiple trials ongoing globally to evaluate efficacy [13]. [6]
MSCs provide dopaminergic neuron support through neurotrophic factor secretion [14]. Motor function improvement observed in early trials [15]. Combined approaches with gene therapy in development [16]. [7]
Immunomodulatory effects may slow disease progression [17]. Phase I/II trials completed demonstrating safety [18]. Mixed results regarding functional improvement in larger studies [19]. [8]
MSC therapy approved in some countries (e.g., Iran, Australia) for MS treatment [20]. Remyelination potential demonstrated in animal models [21]. Autoimmune modulation through MSC immunomodulatory properties [22]. [9]
Both acute and chronic stroke trials have been conducted [23]. Motor recovery improvement reported in multiple studies [24]. Combination with rehabilitation enhances therapeutic benefits [25]. [10]
The study of Mesenchymal Stem Cell Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [11]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [12]
Additional evidence sources: [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25]
Pittenger MF, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999. ↩︎
Shi Y, et al. Immunomodulatory function of mesenchymal stem cells. J Cell Mol Med. 2010. ↩︎
Aggarwal S, et al. Mesenchymal stem cells suppress T cell activation through cell-cell contact. J Immunol. 2005. ↩︎
Crigler L, et al. Mesenchymal stem cell secretion of GDNF, BDNF, and NGF. J Tissue Eng Regen Med. 2007. ↩︎
Sadan O, et al. Neurotrophic factors secreted by mesenchymal stem cells: protective effects on dopaminergic neurons. Mol Neurobiol. 2012. ↩︎
Rani S, et al. Mesenchymal stem cell-derived secretome: a new therapeutic paradigm. Stem Cell Res Ther. 2015. ↩︎
Drago D, et al. MSC secretome for neurodegeneration: therapeutic potential. Front Cell Neurosci. 2013. ↩︎
Islam MN, et al. Mitochondrial transfer from bone marrow stromal cells to lung cancer cells. Cell Stem Cell. 2012. ↩︎
Plotnikov EY, et al. Mesenchymal stem cell mitochondria transfer improves neuronal function. Cell Transplant. 2013. ↩︎
Kim HJ, et al. Safety and efficacy of MSC transplantation in Alzheimer's disease. J Alzheimers Dis. 2020. ↩︎
Gan P, et al. Cognitive improvement following MSC therapy in AD patients. Stem Cell Res Ther. 2018. ↩︎
ClinicalTrials.gov. Mesenchymal stem cells for Alzheimer's disease. NCT02833792, NCT03172117. ↩︎
Shetty P, et al. MSC-mediated neurotrophic support for Parkinson's disease. J Transl Med. 2015. ↩︎
Venkataramana NK, et al. Improved motor function in Parkinson's patients after MSC transplantation. Stem Cell Res Ther. 2010. ↩︎
Song CG, et al. Combined MSC and gene therapy for PD: new strategies. Mol Neurobiol. 2018. ↩︎
Petrou P, et al. MSC therapy for ALS: immunomodulatory effects. JAMA Neurol. 2016. ↩︎
Staff NP, et al. Safety of MSC transplantation in ALS patients. Ann Neurol. 2016. ↩︎
Berry JD, et al. MSC for ALS: results from the phase II trial. Neurology. 2019. ↩︎
Behfar A, et al. Mesenchymal stem cell therapy in Iran: clinical outcomes. Cytotherapy. 2019. ↩︎
Pluchino S, et al. MSC-mediated remyelination in multiple sclerosis models. Nature. 2005. ↩︎
Uccelli A, et al. [MSC immunomodulation in multiple sclerosis](https://doi.org/10.1016/S1474-4422(08). Lancet Neurol. 2008. ↩︎
Lee JS, et al. MSC therapy for stroke: systematic review. Stroke. 2010. ↩︎
Bang OY, et al. Motor recovery after MSC transplantation in stroke. Neurology. 2005. ↩︎
Chen X, et al. MSC plus rehabilitation enhances stroke recovery. Neurorehabil Neural Repair. 2019. ↩︎
Tolar J, et al. Tumorigenicity of mesenchymal stem cells. Stem Cells. 2006. ↩︎